Here are the 10-K annual reports from Ludwig Enterprises (LUDG) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow LUDG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LUDG filings page.
Ludwig Enterprises, Inc. outlines its transformation into an early-stage genomic diagnostics company focused on mRNA-based tests for inflammation-driven cancers, led by its Revealia™ Breast cheek-swab assay, which it anticipates trial-launching in the second quarter of 2026, subject to funding and validation.
The company reports it has no commercial products or revenue and is running preliminary validation, where a 249-patient breast cancer subset showed about 92% sensitivity, 54% specificity, and 86% negative predictive value. More than 3,000 samples have been collected across over 40 U.S. sites, with broader cancer indications in development.
Ludwig highlights significant financial strain: net loss of $2,236,433 in 2025 and $3,016,884 in 2024, with an accumulated deficit of $9,495,799 and auditor “going concern” doubt. The company has raised about $3,000,000 in loans, depends on additional capital to continue operations, and plans a B2B2C, lab-partnered commercialization model while facing intense competition and evolving LDT regulation.